ANGLE plc has signed an agreement with NuProbe USA to use its pan-cancer next generation sequencing panel. NuProbe has granted ANGLE plc an option for an exclusive global license to the NGS panel outside of China for the analysis of CTCs and the dual analysis of CTCs and ctDNA. In the first stage of the collaboration, NuProbe will transfer manufacture of the NGS panel to a larger-scale manufacturing site and ANGLE will undertake internal validation of the initial batches.
NuProbe is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.